Arbutus Biopharma (ABUS) Assets Average (2011 - 2026)

Arbutus Biopharma has disclosed Assets Average across 15 years of filings, most recently posting $185.9 million for Q1 2026.

• Assets Average for Q1 2026 came in at $185.9 million, up 49.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $185.9 million (up 49.48% YoY), and the FY2025 annual result was $113.2 million, down 18.03% from the prior year.
• Assets Average came in at $185.9 million for Q1 2026 at Arbutus Biopharma, up from $96.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $226.4 million in Q2 2022 to a low of $96.2 million in Q4 2025.
• The 5-year median for Assets Average is $155.2 million (2024), against an average of $162.3 million.
• Across the five-year window, Assets Average soared 60.76% in 2022 and plunged 33.12% in 2025, its largest moves.
• Arbutus Biopharma's Assets Average stood at $199.6 million in 2022, then declined by 24.09% to $151.5 million in 2023, then retreated by 10.19% to $136.1 million in 2024, then dropped by 29.33% to $96.2 million in 2025, then surged by 93.31% to $185.9 million in 2026.
• The last three Assets Average figures came in at $185.9 million (Q1 2026), $96.2 million (Q4 2025), and $100.5 million (Q3 2025), per Business Quant data.